Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 2:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 5,194 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Healthy Participant Study Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Immunogenicity, and Dose Ranging Study of Inactivated Zika Virus Vaccine in Healthy Participants

NCT03343626
View directory record Official record
Conditions
Virus, Zika, Zika Virus Disease, Flavivirus Infections, Healthy Participants
Interventions
Placebo, PIZV
Drug · Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 49 Years
Enrollment
271 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
7
States / cities
Coral Gables, Florida • Miami, Florida • Lenexa, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Jun 26, 2026, 2:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Topiramate Sprinkle Capsules 25 mg and Topamax® Sprinkle Capsules 25 mg

NCT00649740
View directory record Official record
Conditions
Healthy
Interventions
Topiramate Sprinkle Capsules 25 mg, Topamax® Sprinkle Capsule 25 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Jun 26, 2026, 2:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 Study of ACE-083 in Healthy Subjects

NCT02257489
View directory record Official record
Conditions
Musculoskeletal Diseases
Interventions
ACE-083
Drug
Lead sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Industry
Eligibility
45 Years to 75 Years · Female only
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Jun 26, 2026, 2:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Tolerability of a Modified Health-Dx

NCT06240650
View directory record Official record
Conditions
Healthy Volunteers
Interventions
modified Health- Dx™ (mHDx) study capsule, modified Health- Dx™ (mHDx) control capsule
Device
Lead sponsor
Celero Systems, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Jun 26, 2026, 2:57 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

MACS and Healthy Volunteers Bone Study

NCT04343560
View directory record Official record
Conditions
MACS Syndrome
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Jun 26, 2026, 2:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Examine the Effects of Entinostat on Midazolam in Healthy Adult Subjects

NCT03187015
View directory record Official record
Conditions
Drug Interaction, Healthy Volunteer
Interventions
Entinostat, Midazolam
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
19 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Jun 26, 2026, 2:57 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

This Study Will Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MET097 in Adult Participants With Overweight or Obesity

NCT06857617
View directory record Official record
Conditions
Obesity and Overweight
Interventions
(Part C) MET097, (Part C) Placebo
Biological
Lead sponsor
Metsera, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
3
States / cities
Anaheim, California • Cypress, California • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Jun 26, 2026, 2:57 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult Participants

NCT07226817
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986435
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 60 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Jun 26, 2026, 2:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study to Compare 3 Different Strengths of an Extended Release Formulation of ASP015K to an Immediate Release Formulation of ASP015K

NCT01686217
View directory record Official record
Conditions
Pharmacokinetics of ASP015K, Food Effect, Healthy Volunteers
Interventions
ASP015K ER, ASP015K IR
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2015 · Synced Jun 26, 2026, 2:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of Y-3 in US Healthy Volunteers.

NCT06770491
View directory record Official record
Conditions
Safety, Tolerability, Pharmacokinetic Study in Healthy Volunteers
Interventions
Y-3 for injection, Placebo
Drug
Lead sponsor
Neurodawn Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Webster, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Jun 26, 2026, 2:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability Study of K0706 in Healthy Subjects

NCT03316820
View directory record Official record
Conditions
Healthy
Interventions
K0706
Drug
Lead sponsor
Sun Pharma Advanced Research Company Limited
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated May 2, 2019 · Synced Jun 26, 2026, 2:57 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Pilot Study: The Effect of Ergocalciferol on Plasma Mucin-1 Levels

NCT03747523
View directory record Official record
Conditions
Ergocalciferol
Interventions
Ergocalciferol
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Jun 26, 2026, 2:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic (PK) Study of Single-dose Rosuvastatin and Tipranavir/Ritonavir in Healthy Subjects

NCT00344123
View directory record Official record
Conditions
HIV Infections
Interventions
Tipranavir/Ritonavir, Rosuvastatin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Jun 26, 2026, 2:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Multiple Doses of CC-90001 on the Pharmacokinetics of Omeprazole, Midazolam, Warfarin, Rosuvastatin, Metformin, Digoxin, and Nintedanib in Healthy Adult Subjects

NCT03363815
View directory record Official record
Conditions
Heathy Volunteer
Interventions
CC-90001, Omeprazole, Midazolam, Warfarin, Vitamin K, Rosuvastatin, Metformin, Digoxin, Nintedanib
Drug · Dietary Supplement
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 64 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Jun 26, 2026, 2:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired Subjects

NCT02857868
View directory record Official record
Conditions
Hepatic Impairment
Interventions
ABL001
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Jun 26, 2026, 2:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics of Vasopressin in Healthy Volunteers

NCT04093050
View directory record Official record
Conditions
Healthy Volunteer Safety Study
Interventions
Vasostrict Injectable Product
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
Orlando, Florida • Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Jun 26, 2026, 2:57 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study of [14C]-LY3023703 in Healthy Participants

NCT01965782
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[^14C]-LY3023703
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Jun 26, 2026, 2:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of NKTR-358 (LY3471851) in Healthy Participants

NCT04380324
View directory record Official record
Conditions
Healthy
Interventions
LY3471851, Placebo
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Jun 26, 2026, 2:57 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Neural and Physiological Correlates of Psychedelic Sub-states

NCT05698511
View directory record Official record
Conditions
Psychedelic Experiences, Neuroimaging, Healthy Volunteers
Interventions
Psilocybin
Drug
Lead sponsor
Robin Carhart-Harris, PhD, MA
Other
Eligibility
21 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jun 26, 2026, 2:57 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Three-part Study to Determine the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Volunteers and Healthy Male Japanese Subjects

NCT01818011
View directory record Official record
Conditions
Infections, Bacterial
Interventions
GSK1322322 Initial fit for purpose tablets, GSK1322322 over granulated tablets, GSK1322322 intended commercial tablets, Placebo tablets, 13C-GSK1322322 stable isotope powder, GSK1322322 for injection, Placebo injection
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Jun 26, 2026, 2:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Human Rhinovirus Type 16 (HRV-16) Following Administration in the Nose of Healthy Adult Volunteers

NCT01466738
View directory record Official record
Conditions
Healthy
Interventions
HRV-16 (100 TCID50), HRV-16 (1000 TCID50)
Biological
Lead sponsor
Centocor Ortho Biotech Services, L.L.C.
Industry
Eligibility
18 Years to 60 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Jun 26, 2026, 2:57 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Study Developed to Evaluate the Effect of ANG-3777 on QT/QTc Interval

NCT04898907
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ANG-3777 (Therapeutic Dose), ANG-3777 (Supra-therapeutic Dose), Placebo, Moxifloxacin Hydrochloride
Drug
Lead sponsor
Angion Biomedica Corp
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 31, 2021 · Synced Jun 26, 2026, 2:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple Ascending Dose Study of Safety and Pharmacokinetics of NP10679 in Normal Healthy Volunteers

NCT04007263
View directory record Official record
Conditions
Stroke, Ischemic, Pain, Postoperative, Substance Abuse, Subarachnoid Hemorrhage
Interventions
Placebo, NP10679
Drug
Lead sponsor
Neurop Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 3, 2019 · Synced Jun 26, 2026, 2:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ACHN-975 in Healthy Volunteers

NCT01597947
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ACHN-975, placebo
Drug
Lead sponsor
Achaogen, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 20, 2013 · Synced Jun 26, 2026, 2:57 PM EDT